Abstract
Aim
The J-SMART study was the first national survey of Japanese patients undergoing laparoscopic sleeve gastrectomy (LSG). We performed a subgroup analysis of J-SMART focusing on the differences in patient background and diabetes remission between patients with BMI 32–34.9 kg/m2 and those with higher BMI.
Methods
In this multi-institutional retrospective study at 10 certified bariatric institutions, 203 Japanese with type 2 diabetes (T2D) and BMI of 32 kg/m2 or higher were analyzed (mean age: 49.2 years, BMI: 43.8 kg/m2, HbA1c: 7.6%). Patients were stratified into five groups according to preoperative BMI.
Results
Background characteristics in BMI 32.0–34.9 group were higher adjusted HbA1c, higher visceral/subcutaneous fat area ratio, higher prevalence of diabetic retinopathy, higher frequency of insulin use and lower serum C-peptide. Although 2-year percent total weight loss (21.7%) and diabetes complete remission (CR) rate (52.4%) were lower in BMI 32.0–34.9 group, diabetes improvement rate was 81.0%, and the decrease in HbA1c and number of antidiabetic drugs were comparable or greater than those with higher BMI. Higher BMI and no insulin use were significant independent predictors of diabetes CR. No significant independent predictor was identified for diabetes improvement.
Conclusion
The patients with 32–34.9 kg/m2 were characterized by more severe visceral obesity, T2D and the complications, and lower intrinsic insulin secretion capacity. LSG should be considered as a treatment option for patients with BMI 32–34.9 kg/m2, to improve diabetes control.
Similar content being viewed by others
References
Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11(3):165–223.
Angrisani L, Santonicola A, Iovino P, et al. IFSO worldwide survey 2016: primary, endoluminal, and revisional procedures. Obes Surg. 2018;28:3783–94.
Ohta M, Kasama K, Sasaki A, Naitoh T, Seki Y, Inamine S, Oshiro T, Doki Y, Seto Y, Hayashi H, Uyama I, Takiguchi S, Kojima K, Mori T, Inomata M, Kitagawa Y, Kitano S, Japan Consortium of Obesity and Metabolic Surgery (JCOMS). Current status of laparoscopic bariatric/metabolic surgery in Japan: The sixth nationwide survey by the Japan Consortium of Obesity and Metabolic Surgery. Asian J Endosc Surg. 2020. https://doi.org/10.1111/ases.12836.
Shah S, Shah P, Todkar J, Gagner M, Sonar S, Solav S. Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus. Surg Obes Relat Dis. 2010;6:152–7.
Saiki A, Yamaguchi T, Tanaka S, Sasaki A, Naitoh T, Seto Y, Japanese Survey of Morbid and Treatment-Resistant Obesity Group (J-SMART Group), et al. Background characteristics and postoperative outcomes of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Ann Gastroenterol Surg. 2019;3(6):638–47.
Bassett J, Organization WH. The Asia-Pacific perspective: redefining obesity and its treatment: Health Communications Australia. 2000. https://apps.who.int/iris/handle/10665/206936.
Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–8.
Ohta M, Seki Y, Wong SK, Wang C, Huang CK, Aly A, Baijal M, Al-Sabah S, Udomsawaengsup S, Heo YS, Althuwaini SS, Celik A, El-Hadidi N, Sargsyan D, Gee T, Rao J, Wiradisuria ER, Oliveros E, Kitano S, Kasama K. Bariatric/metabolic surgery in the Asia-Pacific region: APMBSS 2018 survey. Obes Surg. 2019;29(2):534–41.
Kramer H, Cao G, Dugas L, et al. Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the national health and nutrition examination surveys. J Diabetes Complicat. 2010;24:368–74.
Japan Diabetes Clinical Data Management Study Group. 2017. http://jddm.jp/data/index-2017/.
Rubino F, Nathan DM, Eckel RH, et al. Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77.
Zimmet P, Alberti KG, Rubino F, et al. IDF’s view of bariatric surgery in type 2 diabetes. Lancet. 2011;378:108–10.
Kasama K, Lee WJ, Seki Y, et al. IFSO-APC consensus statements. Obes Surg. 2012;22:677–84.
Seki Y, Kasama K, Kikkawa E, Yokoyama R, Nabekura T, Sano A, Amiki M, Kurokawa Y. Five-year outcomes of laparoscopic sleeve gastrectomy in Japanese patients with class I obesity. Obes Surg. 2020;30(11):4366–74.
Brethauer SA, Kim J, el Chaar M, Papasavas P, Eisenberg D, Rogers A, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11:489–506.
Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14:155–8.
Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.
Rosenthal RJ. International sleeve gastrectomy expert panel consensus statement: best practice guidelines based on experience of >12,000 cases. Surg Obes Relat Dis. 2012;8:8–19.
Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9:379–84.
Singla R, Murthy M, Singla S, Gupta Y. Friendly fat theory—explaining the paradox of diabetes and obesity. Eur Endocrinol. 2019;15(1):25–8. https://doi.org/10.17925/EE.2019.15.1.25 (Epub 2019 Apr 12).
Gravina G, Ferrari F, Nebbiai G. The obesity paradox and diabetes. Eat Weight Disord. 2020. https://doi.org/10.1007/s40519-020-01015-1.
Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146:143–8.
Tuomilehto H, Seppä J, Uusitupa M. Obesity and obstructive sleep apnea—clinical significance of weight loss. Sleep Med Rev. 2013;17(5):321–9. https://doi.org/10.1016/j.smrv.2012.08.002 (Epub 2012 Oct 16).
Ugi S, Morino K, Yamaguchi T, Yamamoto H, Kaida S, Miyazawa I, Sato D, Sekine O, Fujita Y, Kashiwagi A, Tani M, Maegawa H. Preserving β-cell function is the major determinant of diabetes remission following laparoscopic sleeve gastrectomy in Japanese obese diabetic patients. Endocr J. 2019;66(9):817–26. https://doi.org/10.1507/endocrj.EJ19-0054 (Epub 2019 Jun 1).
Umemura A, Sasaki A, Nitta H, Nikai H, Baba S, Takahara T, Hasegawa Y, Katagiri H, Kanno S, Ishigaki Y. Prognostic factors and a new preliminary scoring system for remission of type 2 diabetes mellitus after laparoscopic sleeve gastrectomy. Surg Today. 2020;50(9):1056–64. https://doi.org/10.1007/s00595-020-01990-z (Epub 2020 Mar 13).
Palikhe G, Gupta R, Behera BN, Sachdeva N, Gangadhar P, Bhansali A. Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus. Obes Surg. 2014;24(4):529–35.
Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract. 2007;76(1):93–101. https://doi.org/10.1016/j.diabres.2006.08.004 (Epub 2006 Sep 7).
Ohira M, Yamaguchi T, Saiki A, Nakamura S, Tanaka S, Oka R, Watanabe Y, Sato Y, Oshiro T, Murano T, Tatsuno I. Laparoscopic sleeve gastrectomy significantly increases serum lipoprotein lipase level in obese patients. Obes Facts. 2019;12(3):357–68. https://doi.org/10.1159/000500360 (Epub 2019 Jun 5).
Aminian A, Brethauer SA, Andalib A, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg. 2017;266:650–7.
Chen JC, Hsu NY, Lee WJ, et al. Prediction of type 2 diabetes remission after metabolic surgery: a comparison of the individualized metabolic surgery score and the ABCD score. Surg Obes Relat Dis. 2018;14(5):640–5.
Kim YJ, Kim BH, Choi BM, Sun HJ, Lee SJ, Choi KS. Bariatric surgery is associated with less progression of diabetic retinopathy: a systematic review and meta-analysis. Surg Obes Relat Dis. 2017;13(2):352–60. https://doi.org/10.1016/j.soard.2016.10.002 (Epub 2016 Oct 5).
Hsu CC, Almulaifi A, Chen JC, et al. Effect of bariatric surgery vs medical treatment on type 2 diabetes in patients with body mass index lower than 35: five-year outcomes. JAMA Surg. 2015;150:1117–24.
Amin A, Siddiq G, Haider MI, et al. Laparoscopic sleeve gastrectomy versus lifestyle modification in class I obesity in Pakistani population: a prospective cohort study. Cureus. 2019;11:e5031.
Huang R, Ding X, Fu H, Cai Q. Potential mechanisms of sleeve gastrectomy for reducing weight and improving metabolism in patients with obesity. Surg Obes Relat Dis. 2019;15(10):1861–71. https://doi.org/10.1016/j.soard.2019.06.022 (Epub 2019 Jun 28).
Acknowledgements
The authors wish to thank Aki Hagiwara for the collection and assembly of data.
Funding
J-SMART was supported by a grant for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan (H28-nanji-ippan-014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Naitoh received honorarium from Johnson & Johnson, Inc., Medtronic, Inc. and received research funding from Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C) (#17K10575). Dr. Ishigaki received honorarium from MSD Ltd., Sanofi Ltd., Bayer Yakuhin Ltd., Takeda pharmaceutical Co Ltd., Novo Nordisk Pharma Ltd., Novartis Pharma Ltd., Ono pharmaceutical company, Kowa pharmaceutical Co Ltd., and received donation from Ono pharmaceutical company and MSD Ltd. Dr. Yokote received honorarium from Kowa Company, Ltd., MSD K.K., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Amgen K.K., Takeda Pharmaceutical Company Limited, Sanofi K.K., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Daiichi Sankyo Company, Limited, Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Taisho Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., received research funding from Taisho Pharmaceutical Co., and received donations from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited, MSD K.K., Pfizer Japan Inc., Novo Nordisk Pharma Ltd., Taisho Pharmaceutical Co., Ltd., Kao Corporation, Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Company, Limited, Teijin Pharma Limited, Shionogi Co., Ltd., Astellas Pharma Inc., Kowa Company, Ltd., Bayer Yakuhin, Ltd. Dr. Kasama received honorarium from Johnson & Johnson, Inc., Medtronic, Inc. and received research funding from Medtronic, Inc. The remaining authors have nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Saiki, A., Yamaguchi, T., Sasaki, A. et al. Background characteristics and diabetes remission after laparoscopic sleeve gastrectomy in Japanese patients with type 2 diabetes stratified by BMI: subgroup analysis of J-SMART. Diabetol Int 12, 303–312 (2021). https://doi.org/10.1007/s13340-020-00487-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-020-00487-x